MedPath

C.T. Development America, Inc.

Ownership
Private
Employees
-
Market Cap
-
Website

Clinical Trials

3

Active:0
Completed:3

Trial Phases

2 Phases

Phase 2:2
Phase 3:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials

Phase 2
2 (66.7%)
Phase 3
1 (33.3%)

A Study of RX-10045 in the Treatment of Dry Eye Disease

Phase 2
Completed
Conditions
Dry Eye Syndrome
Interventions
Drug: Vehicle for RX-10045
First Posted Date
2012-08-30
Last Posted Date
2013-02-08
Lead Sponsor
C.T. Development America, Inc.
Target Recruit Count
150
Registration Number
NCT01675570
Locations
🇺🇸

Andover Eye Associates, Andover, Massachusetts, United States

Evaluation of the Onset and Duration of Action of RX-10045 in Allergic Conjunctivitis

Phase 2
Completed
Conditions
Allergic Conjunctivitis
Interventions
Drug: Vehicle for RX-10045 arm
First Posted Date
2012-07-13
Last Posted Date
2013-02-08
Lead Sponsor
C.T. Development America, Inc.
Target Recruit Count
60
Registration Number
NCT01639846
Locations
🇺🇸

Andover Eye Associates, Andover, Massachusetts, United States

Efficacy and Safety Study of KIACTA in Preventing Renal Function Decline in AA Amyloidosis

Phase 3
Completed
Conditions
Amyloidosis
Interventions
Drug: Placebo
Drug: KIACTA (eprodisate disodium)
First Posted Date
2010-10-06
Last Posted Date
2016-03-10
Lead Sponsor
C.T. Development America, Inc.
Target Recruit Count
261
Registration Number
NCT01215747
Locations
🇺🇸

Raffi Minasian MD a Medical Corporation, Glendale, California, United States

🇺🇸

Boston Medical Center, Boston, Massachusetts, United States

🇺🇸

Ohio State University Medical Center, Columbus, Ohio, United States

and more 42 locations

News

No news found
© Copyright 2025. All Rights Reserved by MedPath